Synergistic Antitumor Effects of Histamine Plus Melphalan in Isolated Hepatic Perfusion for Liver Metastases

[1]  A. Eggermont,et al.  Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies. , 2004, Journal of the National Cancer Institute.

[2]  H. Alexander,et al.  The past decade of experience with isolated hepatic perfusion. , 2004, The oncologist.

[3]  R. Tollenaar,et al.  Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. , 2004, European journal of cancer.

[4]  A. Eggermont,et al.  Isolated Hypoxic Hepatic Perfusion With Orthograde or Retrograde Flow in Patients With Irresectable Liver Metastases Using Percutaneous Balloon Catheter Techniques: A Phase I and II Study , 2004, Annals of Surgical Oncology.

[5]  K. Hellstrand,et al.  Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis , 2004, Cancer Immunology, Immunotherapy.

[6]  A. Eggermont,et al.  Isolated hepatic perfusion: experimental evidence and clinical utility. , 2004, The Surgical clinics of North America.

[7]  A. Eggermont,et al.  Tumor Vascular Therapy With TNF , 2004 .

[8]  A. Eggermont,et al.  Tumor vascular therapy with TNF: critical review on animal models. , 2004, Methods in molecular medicine.

[9]  A. Eggermont,et al.  Tumor necrosis factor and isolated hepatic perfusion: from preclinical tumor models to clinical studies. , 2003, Anticancer research.

[10]  A. Eggermont,et al.  Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-α-based isolated hepatic perfusion , 2003, British Journal of Cancer.

[11]  H. Alexander,et al.  Transarterial perfusion of liver metastases. , 2002, Seminars in oncology.

[12]  A. Eggermont,et al.  Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras , 2002, British Journal of Cancer.

[13]  S. Libutti,et al.  Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  A. Eggermont,et al.  Tumor Necrosis Factor-&agr; Augments Tumor Effects in Isolated Hepatic Perfusion With Melphalan in a Rat Sarcoma Model , 2000, Journal of immunotherapy.

[15]  M. Choti,et al.  Management of hepatic metastases. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  A. Eggermont,et al.  Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. , 1998, Annals of surgery.

[17]  I. B. Borel Rinkes,et al.  Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[18]  I. B. Borel Rinkes,et al.  Liver and tumour tissue concentrations of TNF-alpha in cancer patients treated with TNF-alpha and melphalan by isolated liver perfusion. , 1997, British Journal of Cancer.

[19]  C. V. D. van de Velde,et al.  Pharmacological evaluation of experimental isolated liver perfusion and hepatic artery infusion with 5-fluorouracil. , 1991, Cancer research.

[20]  P. Zondervan,et al.  Incidence of spontaneous tumors in a group of retired breeder female brown Norway rats. , 1984, Journal of the National Cancer Institute.

[21]  Ausman Rk.  Development of a technic for isolated perfusion of the liver. , 1961 .

[22]  R. Ausman.  Development of a technic for isolated perfusion of the liver. , 1961, New York state journal of medicine.